Navigation Links
American Oriental Bioengineering Announces Participation in September Investor Conferences
Date:9/4/2007

NEW YORK, Sept. 4 /PRNewswire-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: AOB), a leading manufacturer and distributor of plant-based pharmaceutical and nutraceutical products in China, today announced that the Company will attend the Credit Suisse Asian Technology Conference -- China Day on September 10, 2007 in Shenzhen, China as well as the 3rd Semi-Annual Investor Tour of Mainland China hosted by Brean Murray Carret & Co. on September 11, 2007 in Beijing, China.

AOBO management will meet individually with institutional investors attending the Credit Suisse Asian Technology Conference at the Crowne Plaza Hotel in Shenzhen, China on September 10, 2007. In addition, Tony Liu, CEO of AOBO will join a lunch panel discussion at 1:00 pm Beijing Standard Time along with presenters from other Chinese healthcare companies to discuss the recent developments in the China's healthcare industry. Investors interested in attending this event should contact their Credit Suisse institutional sales representative.

AOBO management is scheduled to present at the Brean Murray China Tour on September 11, 2007 at 12:00 pm Beijing Standard Time at the Grand Hyatt Hotel in Beijing. Attendees are also invited to tour the Company's pharmaceutical manufacturing facility and nutraceutical manufacturing facility in Harbin, China on Saturday, September 8, 2007. Investors interested in attending this event should contact their Brean Murray institutional sales representative.

ABOUT AMERICAN ORIENTAL BIOENGINEERING INC:

American Oriental Bioengineering Inc. (AOBO) is engaged in the development and production of plant-based pharmaceutical products and plant-based nutraceutical products widely distributed throughout China. For more information, visit http://www.bioaobo.com.

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.


'/>"/>
SOURCE American Oriental Bioengineering, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. A disgusting video: U.S. companies sell out Americans
2. Northwestern Mutual, American Family make Computerworlds best IT workplaces
3. Brazilian bio-industry should impress American investors
4. CIO Leadership Series: Byrne Chapman, American Family Insurance
5. Metavante fires 180 North American workers
6. 300 millionth American no cause for eco-alarm
7. American Idol spurs music software
8. Healthcare software addresses "90 million" misclassified Americans
9. Technology and the "American" dream
10. Peters: Innovation the only edge that remains for American business
11. We are American No sex, please
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today announced that ... SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B VHH13 ... cross the cell membrane and bind intracellular STAT3 and inhibit its function. Dysregulation ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that ... Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los ...
(Date:10/10/2017)... ... 10, 2017 , ... Dr. Bob Harman, founder and CEO of VetStem ... The event entitled “Stem Cells and Their Regenerative Powers,” was held ... Harman, DVM, MPVM was joined by two human doctors: Peter B. Hanson, M.D., Chief ...
(Date:10/10/2017)... 2017 SomaGenics announced the receipt of a ... RealSeq®-SC (Single Cell), expected to be the first commercially ... microRNAs) from single cells using NGS methods. The NIH,s ... accelerate development of approaches to analyze the heterogeneity of ... techniques for measuring levels of mRNAs in individual cells ...
Breaking Biology Technology:
(Date:10/4/2017)... a global clinical research organization (CRO), announces the launch of Shadow, ... 2017. Shadow is designed to assist medical writers and biometrics teams ... European Medicines Agency (EMA) in meeting the requirements for de-identifying clinical ... ... Tom ...
(Date:6/30/2017)... Today, American Trucking Associations announced Seeing ... and eye tracking software, became the newest member ... "Artificial intelligence and advanced sensing algorithms ... driver,s attentiveness levels while on the road.  Drivers ... fatigue and prevent potential accidents, which could lead ...
(Date:5/16/2017)... 16, 2017  Veratad Technologies, LLC ( www.veratad.com ), ... and identity verification solutions, announced today they will participate ... May 15 thru May 17, 2017, in ... Trade Center. Identity impacts the lives ... today,s quickly evolving digital world, defining identity is critical ...
Breaking Biology News(10 mins):